PRESS-RELEASE filed Nov 12, 2026 at 16:03 ET
InspireMD reported Q3 2026 revenue of $2.24M, below the $2.0M consensus, and a GAAP net loss of $0.12 per share, narrower than the consensus loss of $0.15. The headline is the FDA approval of CGuard Prime for TCAR procedures, which expands the U.S. addressable market by over 35,000 procedures annually and enables a U.S. commercial re-entry in Q4 2026. However, total revenue fell 11% YoY due to the voluntary recall of the CGuard Prime for CAS delivery system, and the company's cash position dropped to $19.2M from $54.2M at year-end 2025, raising liquidity concerns.